FCCC LOGO Faculty Publications
Martin L , Schilder RJ
Front-line treatment of epithelial ovarian cancer: Focus on the medical oncologists' perspective
American Journal of Cancer. 2005 ;4(4) :221-231
Back to previous list
Epithelial ovarian cancer is the leading cause of death among the gynecologic malignancies. Over the past decade, advances in the field of ovarian carcinoma have brought an improvement in survival. This article focuses on the front-line management of ovarian cancer. While management of this disease is multidisciplinary and access to a trained gynecologic oncology surgeon is important, this article summarizes the most important advances from the medical oncologists' perspective. It also reviews the current standard of care based on disease stage, as well as areas of investigation in the front-line treatment of ovarian cancer. © 2005 Adis Data Information BV. All rights reserved.
11756357 (ISSN) Cited By: 0; Export Date: 25 May 2006; Source: Scopus CODEN: AJCMC Language of Original Document: English Correspondence Address: Schilder, R.J.; Fox Chase Cancer Center; 333 Cottman Avenue Philadelphia, PA 19111, United States; email: Russell.Schilder@fccc.edu References: Jemal, A., Murray, T., Ward, E., Cancer Statistics, 2005 (2005) CA Cancer J Clin, 55, pp. 10-30; Parkin, D.M., Bray, F., Ferlay, J., Global cancer statistics, 2002 (2005) CA Cancer J Clin, 55, pp. 74-108; Ozols, R.F., Schwartz, P.S., Eifel, P.J., Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma (2001) Cancer: Principles and Practice of Oncology, pp. 1597-1632, DeVita VT, Hellman S, editors. Philadelphia (PA): Lippincott Williams and Wilkins; Ozols, R.F., Rubin, S.C., In epithelial ovarian cancer (1997) Principles and Practice of Gynecologic Oncology, pp. 919-986, Hoskins WJ, Perez CA, Young RC, editors. Philadelphia (PA): Lippincott-Raven Publishers; Dupont, N.C., Berman, M.L., Surgical management of epithelial ovarian cancer: A review of the literature (2004) Minerva Ginecol, 56 (6), pp. 547-556, Dec; Von Gruen, V.E., Daly, B.J., Futility: Clinical decisions at the end-of-life in women with ovarian cancer (2005) Gynecol Oncol, 97 (2), pp. 638-644, May; Armstrong, D.K., Relapsed ovarian cancer: Challenges and management strategies for a chronic disease (2002) Oncologist, 7 (5 SUPPL.), pp. 20-28; Young, R.C., Walton, L.A., Ellenberg, S.S., Adjuvant therapy in stage I and stage II epithelial ovarian carcinoma: Results of two prospective randomized trials (1990) N Engl J Med, 322, pp. 1021-1028; DiSaia, P.J., Creasman, W.T., Epithelial ovarian cancer (1997) Clinical Gynecologic Oncology, pp. 282-350, St. Louis (MO): Mosby-Year Book, Inc.; Pfisterer, J., Lortholary, A., Kimmig, R., Paclitaxel/carboplatin vs paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIB-IV: Interim results of a Gynecologic Cancer Intergroup Phase III Trial of the AGO Ovarian cancer Study Group and GINECO (2003) Proc Am Soc Clin Oncol, 22, pp. 446a; (2003) Staging Classifications and Clinical Practice Guidelines of Gynecologic Cancers, http://www.figo.org, September; Heintz, A.P., Odicino, F., Maisonneuve, P., Carcinoma of the ovary in volume 25 of the FIGO annual report on the results of treatment in gynecologic cancer (2003) Int J Gynaecol Obstet, 83 (1 SUPPL.), pp. 135-166, Oct; Griffiths, C.T., Surgical resection of tumor bulk in primary treatment of ovarian carcinoma (1975) J Natl Cancer Inst Monogr, 42, pp. 101-104; Ozols, R.F., Bundy, B.N., Greer, B.E., Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with completely resected stage III ovarian cancer: A GOG Study (2003) J Clin Oncol, 21, pp. 3194-3200; Young, R., Chabner, B., Hibbard, S., Advanced ovarian carcinoma: A prospective randomized trial of melphalan (L-PAM) versus combination chemotherapy (1978) N Engl J Med, 299, pp. 1261-1266; Hoskins, W.J., Bundy, B.N., Thigpen, J.T., The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study (1992) Gynecol Oncol, 47, pp. 159-166; Mutch, D.G., Surgical management of ovarian cancer (2002) Semin Oncol, 29 (1 SUPPL. 1), pp. 3-8; Bristow, R.E., Tomacruz, R.S., Armstrong, D.K., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis (2002) J Clin Oncol, 20, pp. 1248-1259; Eisenkop, S.M., Spirtos, N.M., Montag, D.W., The impact of subspecialty training on the management of advanced ovarian cancer (1992) Gynecol Oncol, 47, pp. 203-209; Nguyen, H.N., Averette, H.E., Hoskins, W., National survey of ovarian carcinoma. Part V: The impact of physician's specialty on patients' survival (1993) Cancer, 72, pp. 3663-3670; Junor, E.J., Hole, D.J., Gillis, C.R., Management of ovarian cancer: Referral to a multidisciplinary team matters (1994) Br J Cancer, 70, pp. 363-370; Elit, L., Bondy, S.J., Paszat, L., Outcomes in surgery for ovarian cancer (2002) Gynecol Oncol, 87, pp. 260-267; Van Der Berg, M.E.L., Van Lent, M., Buyse, M., The effect of debulking surgery after induction chemotherapy on the prognosis of advanced epithelial ovarian cancer (1995) N Engl J Med, 3332, pp. 629-634; Rose, P.G., Nerenstone, S., Brady, M., A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: A Gynecologic Oncology Group Study (2002) Proc Am Soc Clin Oncol, 21, p. 802; Vergote, I.B., De Wever, I., Decloedt, J., Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer (2000) Semin Oncol, 27, pp. 31-36; Ansquer, Y., Leblanc, E., Clough, K., Neoadjuvant therapy for unresectable ovarian carcinoma: A French multicentre study (2001) Cancer, 91, pp. 2329-2334; Schwartz, P.E., Rutherford, T.J., Chambers, J.T., Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival (1999) Gynecol Oncol, 72, pp. 93-99; Vergote, I., DeWever, I., Tjalma, W., Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients (1998) Gynecol Oncol, 71, pp. 431-436; Ozols, R.F., Schwartz, P.S., Eifel, P.J., In Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma (2001) Cancer: Principles and Practice of Oncology, p. 1597, DeVita VT, Hellman S, editors. Philadelphia (PA): Lippincott Williams and Wilkins; Colombo, N., Chiari, S., Maggioni, A., Controversial issues in the management of early epithelial ovarian carcinoma: Conservative surgery and the role of adjuvant therapy (1994) Gynecol Oncol, 55, pp. S47-51; Young, R.C., Brady, M.F., Nieberg, R.K., Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: A Gynecologic Oncology Group Study (2003) J Clin Oncol, 21, pp. 4350-4355; Young, R.C., Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/Carboplatin in early stage ovarian cancer (2000) Semin Oncol, 27 (3 SUPPL. 7), pp. 8-10; Young, R.C., Rose, G., Lage, J., A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A GOG Study (2003) Gynecol Oncol, 88, p. 156; Vergote, I.B., Vergote-DeVos, L.N., Abeler, V.M., Randomized trial comparing cisplatin with radioactive phosphorous or whole-abdomen irradiation as adjuvant treatment of ovarian cancer (1992) Cancer, 69, pp. 741-749; Trimbos, J.B., Parmar, M., Vergote, I., International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma (2003) J Natl Cancer Inst, 95 (2), pp. 105-112; Colombo, N., Guthrie, D., Chiari, S., International collaborative ovarian neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer (2003) J Natl Cancer Inst, 95, pp. 125-132; Trimbos, J.B., Vergote, I., Bolis, G., Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial (2003) J Natl Cancer Inst, 95, pp. 113-125; McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B., Taxol: A unique neoplastic agent with significant activity in advanced ovarian epithelial neoplasms (1989) Ann Intern Med, 111, pp. 273-279; Thigpen, J.T., Blessing, J.A., Ball, H., Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A GOG study (1994) J Clin Oncol, 12, pp. 1748-1753; Rowinsky, E.K., Gilbert, M.R., McGuire, W.P., Sequences of taxol and cisplatin: A phase I and pharmacologic study (1991) J Clin Oncol, 9, pp. 1691-1703; McGuire, W.P., Hoskins, W.J., Brady, M.F., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer (1996) N Engl J Med, 334, pp. 1-6; Piccart, M.J., Bertelsen, K., James, K., Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results (2000) J Natl Cancer Inst, 92, pp. 699-708; Muggia, F.M., Braly, P.S., Brady, M.F., Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A GOG study (2000) J Clin Oncol, 18, pp. 106-115; Parmar, M.K.B., Adams, M., Balestrino, M., Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial (2002) Lancet, 360, pp. 505-515; Bookman, M.A., McGuire III, W.P., Kilpatrick, D., Carboplatin and Paclitaxel in ovarian carcinoma: A phase I study of the GOG (1996) J Clin Oncol, 14, pp. 1895-1902; Niejt, J.P., Engelholm, S.A., Tuxen, M.K., Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer (2000) Clin Oncol, 18, pp. 3084-3092; DuBois, A., Luck, H.J., Meier, W., A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer (2003) J Natl Cancer Inst, 17, pp. 1320-1329; Morgan Jr., R.J., Alvarez, R.D., Armstrong, D.K., NCCN Practice Guidelines in Ovarian Cancer, The National Comprehensive Cancer Center Network. V1.2003; Kaye, S.B., Piccart, M., Aapro, M., Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer: An updated overview (1997) Eur J Cancer, 33 (13), pp. 2167-2170, Nov; Vasey, P.A., Role of docetaxel in the treatment of newly diagnosed ovarian cancer (2003) J Clin Oncol, 21 (10 SUPPL.), pp. 136-144, May 15; Stuart, G.C., First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer (2003) Gynecol Oncol, 90 (3 PART 2), pp. S8-15, Sep; Copeland, L.J., Bookman, M.A., Trimble, E., Clinical trials of newer regimens for treating ovarian cancer: The rationale for Gynecologic Oncology Group protocol GOG 182-ICON5 (2003) Gynecol Oncol, 90 (2 PART 2), pp. S1-7, Aug; Markman, M., Intraperitoneal antineoplastic drug delivery: Rationale and results (2003) Lancet Oncol, 4 (5), pp. 277-283, May; Alberts, D.S., Liu, P.Y., Hannigan, E.V., Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclo phosphamide for stage III ovarian cancer (1996) N Engl J Med, 335, pp. 1950-1955; Gadducci, A., Carnino, F., Chiara, S., Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced EOC: A randomized trial of the Gruppo Oncologico Nord-Ovest (2000) Gynecol Oncol, 76, pp. 157-162; Markman, M., Bundy, B.N., Albert, D.S., Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the GOG, SWOG and ECOG (2001) J Clin Oncol, 19, pp. 1001-1007; Armstrong, D.K., Bundy, B.N., Baergen, R., Randomized phase III study of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in optimal stage II epithelial ovarian cancer: A GOG Trial (GOG 172) (2002) Proc Am Soc Clin Oncol, 21, pp. 201a; Guastalla, J.P., Lhomme, C., Kerbrat, P., Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Federation Nationale des Centres de Lutte Contre le Cancer (1994) Ann Oncol, 5, pp. 127-132; Malmstrom, H., Simonsen, E., Westberg, R., A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients (1994) Gynecol Oncol, 52, pp. 20-25; Fujiwara, K., Sakuragi, N., Suzuki, S., First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: Results of long-term follow-up (2003) Gynecol Oncol, 90, pp. 637-643; Levin, L., Hryniuk, W.M., Dose intensity analysis of chemotherapy regimens in ovarian carcinoma (1987) J Clin Oncol, 5, pp. 756-767; Bruckner, H.W., Wallach, R., Cohen, C.J., High-dose cisplatin for the treatment of refractory ovarian cancer (1981) Gynecol Oncol, 12, pp. 64-67; Barker, G.H., Wiltshaw, E., Use of high-dose cis-dichlorodiammine platinum (II) [NSC-119875] following failure on previous chemotherapy for advanced carcinoma of the ovary (1981) Br J Obstet Gynaecol, 88, pp. 1192-1199; Ozols, R.F., Ostchega, Y., Meyers, C.E., High-dose cisplatin in hypertonic saline in refractory ovarian cancer (1985) J Clin Oncol, 2, pp. 1246-1250; Aghajanian, C., Fennelly, D., Shapiro, F., Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer (1998) J Clin Oncol, 16, pp. 1852-1860; Schilder, R.J., Brady, M.F., Spriggs, D., Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: A GOG study (2003) Gynecol Oncol, 88, pp. 3-8; Schilder, R.J., Gallo, J.M., Millenson, M.M., Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy (2001) J Clin Oncol, 19, pp. 1183-1194; Stiff, P.J., Vuem-Stone, J., Lazarus, H.M., High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry report (2000) Ann Intern Med, 133 (7), pp. 504-515, Oct 3; Legros, M., Dauplat, J., Fleury, J., High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results (1997) J Clin Oncol, 15 (4), pp. 1302-1308, Apr; Cure, H., Battista, H., Guastalla, J.P., Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): Preliminary results of a GINECO/FNCLCC/SFGM-TC study (2001) Proc Am Soc Clin Oncol, pp. 815a; Hakes, T.B., Chalas, E., Hoskins, W.J., Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma (1992) Gynecol Oncol, 45, pp. 284-289; Bertelsen, K., Jakobsen, A., Stroyer, J., A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer a Danish Ovarian Study Group trial (DACOVA) (1993) Gynecol Oncol, 49, pp. 30-36; Markman, M., Liu, P.Y., Wilczynski, S., Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A SWOG and GOG trial (2003) J Clin Oncol, 21, pp. 2460-2465; Markman, M., Bookman, M.A., Second-line treatment of ovarian cancer (2000) Oncologist, 5 (1), pp. 26-35; Young, R.C., Decker, D.G., Wharton, J.T., Staging laparotomy in early ovarian cancer (1983) JAMA, 250, pp. 3072-3076; Thigpen, J.T., Vance, R.B., Khansur, T., Second-line chemotherapy for recurrent carcinoma of the ovary (1993) Cancer, 71 (4 SUPPL.), pp. 1559-1564; Harries, M., Gore, M., Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease (2002) Lancet Oncol, 3 (9), pp. 537-545, Sep; Gronlund, B., Hogdall, C., Hansen, H.H., Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer (2001) Gynecol Oncol, 83, pp. 128-134; Parmar, M.K., Ledermann, J.A., Colombo, N., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial (2003) Lancet, 361 (9375), pp. 2099-2106; Ten Bokkel Huinink, W., Gore, M., Carmichael, J., Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (1997) J Clin Oncol, 15, pp. 2183-2193; Fennelly, D., Aghajanian, C., Shapiro, F., Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer (1997) J Clin Oncol, 15 (1), pp. 187-192, Jan; Niwa, Y., Nakanishi, T., Kuzuya, K., Salvage treatment with docetaxel for recurrent epithelial ovarian cancer (2003) Int J Clin Oncol, 8 (6), pp. 343-347, Dec; Creemers, G.J., Bolis, G., Gore, M., Topotecan, an active drug in the 2nd-line treatment of epithelial ovarian cancer: Results of a large European phase II study (1996) J Clin Oncol, 14 (12), pp. 3056-3061; Bookman, M.A., Malmstrom, H., Bolis, G., Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel (1998) J Clin Oncol, 16 (10), pp. 3345-3352, Oct; Rose, P.G., Blessing, J.A., Mayer, A.R., Prolonged oral etoposide as second-line therapy for platinum resistant and platinum-resistant ovarian carcinoma: A GOG Study (1998) J Clin Oncol, 16, pp. 405-410; Shapiro, J.D., Millward, M.J., Rischin, D., Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel (1996) Gynecol Oncol, 63 (1), pp. 89-93, Oct; Friedlander, M., Millward, M.J., Bell, D., A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer (1998) Ann Oncol, 9 (12), pp. 1343-1345, Dec; Muggia, F.M., Hainsworth, J.D., Jeffers, S., Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation (1997) J Clin Oncol, 15 (3), pp. 987-993, Mar; Gordon, A.N., Fleagle, J.T., Guthrie, D., Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan (2001) J Clin Oncol, 19 (14), pp. 3312-3322, Jul 15; Righetti, S.C., Della Torre, G., Pilotti, S., A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma (1996) Cancer Res, 56 (4), pp. 689-693, Feb; Berchuck, A., Bast Jr., R.C., p53-Based gene therapy of ovarian cancer: Magic bullet? (1995) Gynecol Oncol, 59, pp. 169-170; Buller, R.E., Runnebaum, I.B., Karlan, B.Y., A phase I/II trial of rAd/p53 (SCH58500) gene replacement in recurrent ovarian cancer (2002) Cancer Gene Ther, 9, pp. 553-566; Buller, R.E., Shahin, M.S., Horowitz, J.A., Long-term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 (2002) Cancer Gene Ther, 9, pp. 567-572; Berek, J.S., Schultes, B.C., Nicodemus, C.F., Biologic and immunologic therapies for ovarian cancer (2003) J Clin Oncol, 21 (10 S), pp. 168s-74s; Raymond, E., Faivre, S., Armand, J.P., Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy (2000) Drugs, 60 (1 SUPPL.), pp. 15-23; Schilder, R.J., Kohn, E., Sill, M.W., Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer: Gynecology Oncology Group 170C (2003) Proc Am Soc Clin Oncol, 22, p. 1814; Herbst, R.S., Erlotinib (Tarceva): An update on the clinical trial program (2003) Semin Oncol, 3 (7 SUPPL.), pp. 34-46; Bookman, M.A., Darcy, K.M., Clarke-Pearson, D., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the GOG (2003) J Clin Oncol, 21 (2), pp. 283-290, Jan 15; Burger, R.A., Sill, M., Monk, B.J., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) [abstract no. 5009]. A Gynecologic Oncology Group (GOG) Study (2005) Proc Am Soc Clin Oncol, 23, pp. 16S; Abramson, N., Stokes, P.K., Luke, M., Ovarian and papillary serous peritoneal carcinoma: Pilot study with thalidomide (2002) J Clin Oncol, 20, pp. 1147-1149; Hirte, H.W., Vergote, I.B., Jeffrey, J., An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients with advanced ovarian cancer responsive to primary surgery/paclitaxel and platinum containing chemotherapy (2001) Proc Am Soc Clin Oncol, 20, pp. 209a, abstract no. 832; DiSaia, P.J., Bloss, J.D., Treatment of ovarian cancer: New strategies (2003) Gynecol Oncol, 90, pp. S24-32.